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Abstract T cells engineered to express a tumor-specific ab T cell receptor (TCR) mediate anti-
tumor immunity. However, mispairing of the therapeutic ab chains with endogenous ab chains
reduces therapeutic TCR surface expression and generates self-reactive TCRs. We report a general
strategy to prevent TCR mispairing: swapping constant domains between the a and b chains of a
therapeutic TCR. When paired, domain-swapped (ds)TCRs assemble with CD3, express on the cell
surface, and mediate antigen-specific T cell responses. By contrast, dsTCR chains mispaired with
endogenous chains cannot properly assemble with CD3 or signal, preventing autoimmunity. We
validate this approach in cell-based assays and in a mouse model of TCR gene transfer-induced
graft-versus-host disease. We also validate a related approach whereby replacement of ab TCR
domains with corresponding gd TCR domains yields a functional TCR that does not mispair. This
work enables the design of safer TCR gene therapies for cancer immunotherapy.
DOI: 10.7554/eLife.19095.001
Introduction
T lymphocytes recognize cellular targets with extraordinary sensitivity and specificity. The T cell
receptor (TCR) on the T cell surface binds to its cognate peptide antigen presented on major histo-
compatibility complex (MHC) molecules on the target cell surface (Reinherz, 2015). The TCR - a het-
erodimer that is uniquely rearranged in each T cell during its development - is the sole determinant
of T cell specificity (DembiC´ et al., 1986). Accordingly, transfer of the a and b genes encoding a
tumor-reactive ab TCR can impart anti-tumor reactivity to a cancer patient’s T cells (Clay et al.,
1999). Upon reinfusion into the patient, these engineered T cells mediate potent anti-tumor cytotox-
icity (Park et al., 2011). This approach – termed TCR gene therapy – has demonstrated clinical
responses for several malignancies (Johnson et al., 2009; Morgan et al., 2006; Davis, 2010; Par-
khurst, 2011; Robbins et al., 2015, 2011), which may be bolstered in the future through combina-
tion with complementary immunotherapies like dendritic cell-based vaccination and checkpoint
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blockade (Abate-Daga et al., 2013; Brahmer and Hammers, 2015; Mellman et al., 2011;
Sharma and Allison, 2015; Topalian et al., 2015; Chodon, 2014).
Despite the promise of TCR gene therapy, there remain significant limitations to its safety and
efficacy. Among these is that TCR-transduced ab T cells express two a and two b chains, a non-phys-
iological situation in which the introduced TCR a and b chains can mispair with the endogenous TCR
b and a chains, respectively. TCR chain mispairing reduces the level of correctly-paired, tumor-reac-
tive TCR heterodimers expressed on the T cell surface, possibly reducing therapeutic efficacy
(Jorritsma et al., 2007). More ominously, mispairing can generate self-reactive TCR heterodimers
that do not undergo thymic negative selection. These mispaired TCRs engender autoreactivity in
TCR-transduced human T cells in vitro (van Loenen et al., 2010) and mediate lethal graft-versus-
host disease in mice administered TCR-transduced T cells following a protocol mimicking human
clinical trials (Bendle et al., 2010; Bunse, 2014). Although no serious adverse events have been
attributed to TCR mispairing in engineered T cell trials (Rosenberg, 2010), autoreactive off-target
and off-tumor engineered T cell responses have caused deaths (Linette et al., 2013; Morgan et al.,
2013, 2010). These underscore the need to safeguard against TCR mispairing-related autoreactiv-
ity, particularly as more potent immunotherapy regimes are employed.
Efforts to prevent TCR mispairing can be broadly categorized as either engineering the trans-
duced TCR (adding interchain disulfide bonds, murinizing portions of the TCR, expressing TCR as a
single chain) (Uckert and Schumacher, 2009) or reducing expression of the endogenous TCR
(shRNA knockdown (Bunse, 2014; Okamoto et al., 2009) or genomic knockout [Provasi et al.,
2012]). Although several engineering strategies improve pairing between the transduced chains,
complete prevention of mispairing has not been achieved (Thomas et al., 2007) and murine TCRs
eLife digest T cells enable the immune system to recognize invading microbes and diseased
cells while ignoring healthy cells. The ability of a T cell to recognize a specific microbe or diseased
cell is determined by two proteins that pair to form its “T cell receptor.” The paired receptors are
exported to the surface of the T cell, where they bind to infected or cancerous cells. Those T cells
that produce receptors that bind healthy cells are eliminated during development.
T cells can generally distinguish between the body’s own cells and the cells of invading bacteria
or other microbes. However, cancer cells are more difficult to identify because they are similar to
healthy cells. Efforts to develop therapies that enhance the immune system’s ability to recognize
cancer cells have had only limited success. One successful approach – known as T cell receptor gene
therapy – modifies T cells to destroy cancer cells by arming them with a cancer-specific T cell
receptor.
This technique produces T cells possessing two T cell receptors – the cancer-specific receptor
and the one it had originally – so it is possible for proteins from the two receptors to mispair. This
impedes the correct pairing of the cancer-specific T cell receptor, reducing the effectiveness of the
therapy. More importantly, mispaired T cell receptors may cause the immune cells to attack healthy
cells in the body, leading to autoimmune disease. To make T cell receptor gene therapy safe, the
cancer-specific receptor must not mispair with the resident receptor.
Here, Bethune et al. describe a new strategy to prevent T cell receptors from mispairing. The
researchers altered the arrangement of particular regions in a cancer-specific T cell receptor to make
a new receptor called a domain-swapped T cell receptor (dsTCR). Like normal T cell receptors, the
dsTCRs were exported to the T cell surface and were able to interact with other proteins involved in
immune responses. Furthermore, T cells armed with dsTCRs were able to kill cancer cells and
prevent tumor growth in mice. Unlike other cancer-specific receptors, dsTCRs did not mispair with
the resident T cell receptors in mouse or human cells, and did not cause autoimmune disease in
mice.
The findings of Bethune et al. show that the structure of the T cell receptor is unexpectedly
robust, in that it still works even if it is modified. The next step is to study dsTCRs in more detail
with the aim of optimizing them so that they might be used in human clinical trials in the future.
DOI: 10.7554/eLife.19095.002
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are immunogenic (Davis, 2010). Endogenous TCR knockout prevents mispairing, but the extensive
processing currently required to generate these cells is incompatible with clinical protocols. The
ideal solution will prevent mispairing entirely, eliminating the risk of autoimmunity. Additionally,
modifications made to the introduced TCR chains should avoid foreign sequences to minimize immu-
nogenicity. Finally, these modifications must be restricted to the constant TCR domains, such that
they can be applied without further optimization to any TCR of therapeutic interest. We describe a
novel approach for preventing TCR mispairing that meets these criteria. We show that this approach
is further improved by combining it with the complementary strategy of endogenous TCR
knockdown.
Results
Domain-swapped TCR (dsTCR) design
Our approach to prevent TCR mispairing exploits the molecular requirements for TCR biogenesis
and function. The TCR a and b chains each contain a membrane-distal variable immunoglobulin
domain (V), which imparts specificity, and several constant domains including a membrane-proximal
constant immunoglobulin domain (C), a connecting peptide (cp), a transmembrane helix (TM), and a
short cytoplasmic tail (cyto) (Figure 1A). To achieve functional form, the TCR ab heterodimer must
assemble with six additional chains (CD3 dimers ge, de, and z2), which facilitate export of the TCR
Figure 1. Schematic outlining the domain-swapped TCR strategy. (A) The TCR/CD3 complex comprises the
antigen-specific variable (V) Ig domain and constant domains (constant Ig, C; connecting peptide, cp;
transmembrane helix, TM; and cytoplasmic tail, cyto), which assemble with CD3 chains. CD3 chains are required
for export of the TCR/CD3 complex to the cell surface and for signaling. Parallel horizontal lines represent the cell
membrane. (B) Schematic showing key interactions between basic residues in the TCR TM domain and acidic
residues in the CD3 TM domains. (C) Domain-swapped TCRs retain all domains of the wild-type TCR with altered
covalent connectivity. (D) Mispairing between therapeutic and endogenous TCR chains can result in autoreactivity
(middle). Mispairing between domain-swapped therapeutic and endogenous TCR chains will result in
heterodimers that lack constant domains needed to assemble with CD3, preventing surface expression and
function of potentially autoreactive TCRs (right). Domain-swapped TCRs are thus expected to be functional but
incapable of mediating mispairing-related autoreactivity.
DOI: 10.7554/eLife.19095.003
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complex to the cell surface and mediate signal transduction upon antigen binding (Call and
Wucherpfennig, 2005). If the TCR/CD3 complex is not assembled properly prior to export, it is
degraded (Bonifacino, 1989). Assembly with CD3 requires contacts within the constant domains of
both the TCR a and b chains (Call et al., 2002; Kuhns and Davis, 2007; Xu and Call, 2006), most
critically the basic residues within the transmembrane domains (Call et al., 2002)(Figure 1B). We
designed interchain domain-swapped (ds) TCRs in which select constant domains of the TCR a and
b chains are exchanged in a reciprocal manner (Figure 1C). Correctly paired a/b dsTCRs retain all
domains necessary to assemble with CD3 and to enact tumor-targeted immunity. By contrast, mis-
paired heterodimers comprising one dsTCR chain and one wild-type (wt) TCR chain lack domains
necessary to assemble with CD3 or to enact autoimmune responses (Figure 1d).
Domain-swapped TCRs (dsTCR) assemble with CD3 and express on the
cell surface
We designed three dsTCR architectures in which a and b constant domains were swapped at the
V-C junctions (dsTCRV), at the C-cp junctions (dsTCRC), or at the cp-TM junctions (dsTCRcp)
(Figure 2A). Initially, we generated these dsTCR variants for the HLA-A2-restricted, MART1-specific
F5 TCR (Johnson et al., 2006) (Figure 2—figure supplement 1). We transfected CD3+ 293T cells
Figure 2. Domain-swapped TCRs assemble with CD3 and retain antigenic specificity. (A) Schematic of dsTCR
architectures. Domains are swapped following the V domains (dsTCRV), C domains (dsTCRC), or connecting
peptides (dsTCRcp). (B) Flow cytometric analysis of peptide-MHC multimer binding by CD3+ 293T transfected with
F5 wtTCR or dsTCRs. (C) Flow cytometric analysis comparing peptide-MHC multimer binding by CD3+ 293T
transfected with F5 wtTCR, dsTCRC, or simulated mispaired constructs. Schematics of constructs are above
corresponding data. (D–E) Flow cytometric analysis comparing anti-Vb antibody binding by CD3 + 293T
transfected with wtTCR, dsTCRC, or simulated mispaired constructs for (D) two additional human TCRs and (E)
mouse OTI TCR. Means ± SD for two replicate transfections are shown.
DOI: 10.7554/eLife.19095.004
The following figure supplements are available for figure 2:
Figure supplement 1. Amino acid sequences of initial domain-swapped TCR construct chimeric junctions.
DOI: 10.7554/eLife.19095.005
Figure supplement 2. Optimization of domain-swapped junctions for dsTCRV and dsTCRcp.
DOI: 10.7554/eLife.19095.006
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with each F5 TCR variant and evaluated A2/MART1 tetramer binding by flow cytometry. The dsTCRV
construct did not bind tetramer (Figure 2B), and variation of the precise position at which the V
domains were exchanged did not rectify this (Figure 2—figure supplement 2A). However, both F5
dsTCRC and dsTCRcp bound tetramer, indicating these architectures express on the cell surface and
retain specificity for their cognate ligand (Figure 2B). Cells transfected with F5 dsTCRC bound tetra-
mer with comparable avidity to wtTCR, whereas tetramer binding for dsTCRcp was lower. We varied
the position at which the domains were exchanged in the dsTCRcp architecture to identify the opti-
mal design for this construct (a1b5, Figure 2—figure supplement 2B). The dsTCRC and optimized
dsTCRcp constructs were selected for further investigation.
We posit that dsTCRs are safer than wtTCR because mispaired TCRs comprising one ds and one
wtTCR chain should have impaired capacity to assemble with CD3 and express on the cell surface.
To determine whether dsTCR chains properly assemble CD3 when mispaired with a wtTCR chain, we
prepared hybrid constructs in which only the a or b chain of F5 TCR was domain-swapped at the
C-cp junction, and tested for expression on the surface of CD3+ 293T (Figure 2C). As expected,
compared to fully wtTCR or dsTCRC, surface expression of these simulated mispaired constructs was
significantly reduced, indicating impaired assembly of CD3.
To have broad therapeutic potential, our approach must be applicable to any human TCR of clini-
cal interest without further optimization. Ideally, this approach should also be applicable to murine
TCRs, enabling preclinical studies of safety and efficacy. We constructed dsTCRC and hybrid wt/ds
variants of two additional clinically relevant human TCRs – HLA-A2/MART1-specific M1 TCR
(Chhabra et al., 2008) and HLA-A2/NY-ESO-1-specific 1 G4 TCR (Chen et al., 2000)–as well as the
H-2Kb/ovalbumin-specific OTI murine TCR. For both additional human TCRs as well as the murine
TCR, dsTCR derivatives express on the surface of CD3+ 293T and mitigate mispairing with wtTCR
chains (Figure 2D,E), suggesting this approach can be applied generally to human and mouse TCRs.
dsTCRs are functional in lymphocytes
Altering the spatial relationship between constant TCR domains could potentially alter the orienta-
tion of CD3 chains in the TCR/CD3 complex, impairing its function. To compare the orientation of
CD3 chains around wt- and dsTCRs, we used a dimerization reporter assay previously employed to
determine the orientation of CD3 chains around the ab wtTCR (Kuhns et al., 2010). The murine
pro-B cell line, BaF3, will grow in the absence of IL-3 only when provided Jak-Stat signaling via
dimerized signaling domains of the erythropoietin receptor (EpoR). A fusion of CD3e to EpoR (eE)
was previously shown to drive proliferation of BaF3 when incorporated in the TCR/CD3 complex,
indicating that the CD3 de and ge dimers cluster on one face of the wtTCR, juxtaposing the CD3e
chains (Kuhns et al., 2010) (Figure 3A). We transduced BaF3 cells with all CD3 chains, including eE,
and either human F5 wtTCR, dsTCRC, or dsTCRcp and then measured TCR/CD3 complex on the cell
surface. All three TCRs formed complexes with CD3/eE and bound cognate peptide-MHC multimer
(Figure 3—figure supplement 1). Following removal of IL-3 from the cell media, eE drove prolifera-
tion of BaF3 cells when complexed with wtTCR, dsTCRC, or dsTCRcp, indicating that dsTCRs assem-
ble with CD3 chains in the same orientation as wtTCR (Figure 3B). Results were similar for the
murine OTI TCR (Figure 3C and Figure 3—figure supplement 1).
In both the 293T and BaF3 assays, CD3 chains are expressed at high, non-physiological levels.
We have observed that some TCR is exported to the surface of transfected 293Ts even when CD3
assembly is incomplete (i.e. 26%, 0%, 52%, and 100% residual export respectively when omitting
CD3d, CD3e, CD3g, or CD3z from transfection). We suspected that this accounted for the low level
of apparent pairing between dsTCR and wtTCR chains observed on 293T cells (Figure 2C–E). To
determine whether dsTCRs form a complex with endogenous CD3 in T cells, we transduced the
Jurkat human T cell line with wt- and dsTCRs and used flow cytometry to assess surface expression.
Both dsTCRC and dsTCRcp assemble endogenous CD3, express on the cell surface, and bind cog-
nate A2/MART1 multimers to an extent similar to the wtTCR (Figure 3D). By contrast, hybrid con-
structs comprising one dsTCR chain and one wtTCR chain were not detectable on the surface of
transduced Jurkat cells, indicating that, as expected, these mispaired constructs failed to form a
mature complex (Figure 3E). Virtually all transduced (Myc271+) cells were positive for A2/MART1
staining (Figure 3F), indicating the dsTCRs competed favorably for CD3 recruitment in the presence
of the endogenous Jurkat TCR. To determine whether dsTCR/CD3 complexes are functional, dsTCR-
transduced Jurkat T cells were coincubated with K562 target cells expressing either cognate A2/
Bethune et al. eLife 2016;5:e19095. DOI: 10.7554/eLife.19095 5 of 24
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Figure 3. Domain-swapped TCRs are functional in lymphocytes. (A) Schematic of the BaF3 proliferation assay for
determining CD3 orientation within the TCR/CD3 complex. CD3e-EpoR fusion proteins promote IL-3-independent
proliferation of BaF3 only if assembly in the TCR/CD3 complex orients them in juxtaposition to one another. (B-C)
CD3e-EpoR-driven proliferation of BaF3 cells expressing wild-type and domain-swapped (B) human F5 TCR and (C)
mouse OTI TCR. Cell number was measured 72 hr after IL-3 deprivation. Means ± SD for 3 independent
experiments are shown. (D-E) Representative flow cytometry histograms comparing peptide-MHC multimer
binding by Jurkat T cells transduced with (D) F5 wtTCR or dsTCR constructs or (E) simulated mispaired constructs.
Multimer binding is reliant on cell surface expression following assembly with endogenous CD3 chains. (F) Flow
cytometric measurement of TCR and Myc271 expressed on the surface of transduced Jurkats. Myc271 is an
independent transduction marker expressed from the same vector as TCR. (G) ELISA measuring secretion of IL-2
from TCR-transduced Jurkats following 48 hr coincubation with cognate or control antigen-expressing K562 target
cells. (H) Flow cytometric measurement of dextramer-binding TCR and LNGFR expressed on the surface of
transduced primary human T cells. LNGFR is an independent transduction marker expressed from the same vector
as TCR. (I) ELISA measurement of secreted IFN-g and (J) flow cytometric measurement of CD25 expressed on the
T cell surface from TCR-transduced primary human T cells following 48 hr coincubation with cognate or control
antigen-expressing K562 target cells. For panels (f-j), means ± SD for 3 technical replicates are shown.
DOI: 10.7554/eLife.19095.007
The following figure supplement is available for figure 3:
Figure supplement 1. Domain-swapped TCRs are expressed on the surface of CD3+ BaF3 cells.
DOI: 10.7554/eLife.19095.008
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MART1 or control A2/NYESO1 single-chain trimer (Hansen et al., 2009). Consistent with multimer
staining results, dsTCRs mediated antigen-specific release of IL-2, whereas hybrid wt/dsTCRs simu-
lating mispairing did not (Figure 3G).
Unlike the Jurkat T cell line, primary T cells express a diverse repertoire of endogenous T cell
receptors, which may mispair or compete for surface expression with the transduced TCR to differ-
ing extents across cells. We therefore transduced primary T cells with wt- and dsTCRs to assess their
function in a more physiologically relevant context. As expected, wtTCR was detected in only a sub-
set (74%) of transduced (LNGFR+) cells, indicating ~25% of T cells express an endogenous TCR that
out-competes F5 TCR for CD3 recruitment and cell surface expression (Figure 3H). Dextramer stain-
ing was lower for dsTCRs than wtTCRs in primary T cells (25% and 11% of LNGFR+ cells, for dsTCRC
and dsTCRcp, respectively; MFI = 21% and 13% that of wtTCR). This indicates a larger subset of
endogenous TCRs outcompete the dsTCRs for CD3 recruitment. Nonetheless, T cells transduced
with either wtTCR or dsTCRs were functional, secreting IFN-g and upregulating cell surface CD25 in
an antigen-specific manner when coincubated with target cells (Figure 3I,J). As with Jurkat cells,
simulated mispaired constructs elicited no such activation (Figure 3I,J). Thus, dsTCRs assemble with
endogenous CD3 to mediate antigen-specific immunity in primary lymphocytes and are rendered
nonfunctional when mispaired with wtTCR chains.
dsTCRs do not mispair with endogenous TCR and do not cause graft-
versus-host disease
Transduced a and b chains can each mispair with endogenous chains, and autoreactivity is an unpre-
dictable result of the particular transduced and endogenous chains involved (van Loenen et al.,
2010). To investigate whether dsTCR chains can mispair with any of the diverse array of endogenous
TCR chains expressed across primary T cells, we devised an assay for measuring mispairing without
regard to antigenic specificity. We tagged the N-termini of the a and b chains of F5 TCR with cMyc
and V5 epitope tags, respectively, and confirmed that the addition of these tags did not alter TCR
surface expression on Jurkat T cells (Figure 4—figure supplement 1). We then delivered each chain
individually (i.e. Myc-a only or V5-b only), such that the export of the tagged TCR chain is dependent
on mispairing with endogenous TCR chains. The wta and wtb chains of F5 TCR mispaired with
endogenous TCR chains in 88% and 58% of transduced T cells, respectively. By contrast, neither dsa
nor dsb chains exhibited detectable mispairing with endogenous TCR chains (Figure 4A). Similar
results were obtained with the murine OTI TCR: wta and wtb chains were mispaired in 63% and 84%
of transduced murine T cells, whereas mispairing was not observed with dsa or dsb chains
(Figure 4B). Thus, even when mispairing propensity is maximized by transduction of a single dsTCR
chain in the absence of stoichiometric expression of its correct partner, dsTCR chains exhibit no
detectable mispairing with endogenous TCR chains.
To determine whether dsTCRs prevent deleterious autoimmunity resulting from TCR mispairing,
we used a previously reported mouse model for TCR gene transfer-induced graft-versus-host disease
(TI-GvHD) (Bendle et al., 2010). Mice that develop TI-GvHD due to TCR chain mispairing exhibit
destruction of the hematopoietic compartment and rapid weight loss, generally necessitating sacri-
fice within 1–2 days of onset of cachexia. We transduced T cells with wt- and dsTCR derivatives of
OTI TCR, as this TCR resulted in the highest incidence of TI-GvHD of those TCRs tested in the initial
report of the model. Based on our finding that dsTCR chains do not mispair with endogenous TCR
chains, we expected to recapitulate TI-GvHD in wtTCR-transduced T cell recipients, but not in
dsTCR-transduced T cell recipients. Indeed, mice that received wtTCR(IRES)-transduced T cells - in
which the transduced wtTCR chains were linked by an internal ribosome entry site (IRES) sequence –
exhibited significant cachexia following IL-2 administration (Figure 4C). Although some of these
mice regained weight and survived, 47% (7/15) developed TI-GvHD to an extent that necessitated
euthanasia (Figure 4D). Consistent with previous results (Bendle et al., 2010), the incidence of TI-
GvHD could be reduced but not eliminated by replacing the IRES with a viral 2A sequence to ensure
stoichiometric expression of the wtTCR chains. In this wtTCR(2A) group, less weight loss was
observed and only 1/15 mice developed fatal TI-GvHD. By contrast, cachexia was not observed for
mice that received dsTCRC(2A)-transduced T cells, and none (0/25) of these mice developed TI-
GvHD. Thus, dsTCRs prevent mispairing and thereby prevent mispairing-related autoimmune com-
plications in a model of TCR gene therapy.
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Figure 4. Domain-swapped TCRs do not mispair with endogenous TCRs and do not cause graft-vs-host disease.
(A-B) Flow cytometric measurement of mispairing of (A) human F5 TCR chains in human peripheral blood T cells
and (B) murine OTI TCR chains in murine splenic T cells. Cells were transduced with only TCRa (left panel) or only
TCRb (right panel) such that expression of the introduced chain on the cell surface required mispairing with
endogenous TCR chains. Representative histograms are displayed above bar graphs quantifying means ± SD for 3
technical replicates. (C-D) Mouse model of TCR gene transfer-induced graft-vs-host disease (TI-GvHD). Mice were
irradiated on day -1, administered TCR-transduced T cells on day 0, and injected twice daily with IL-2 from day 10–
12. Weight was monitored daily and mice were euthanized at 85% initial body weight. Results are aggregated
from 3 independent experiments. Respective group sizes, n = 9, 15, 15, and 25. *p<0.05, ****p<0.0001, ns, not
significant. (C) Percent initial body weight of surviving mice at 16 days after T cell administration. (D) Kaplan-Meier
survival curve. (E) Tumor size in mice administered TCR-transduced T cells and then injected with ovalbumin-
expressing E.G7 thymoma tumor cells. Respective group sizes, n = 9, 6, 10, and 10. Mean ± SD for each group is
overlaid on traces for individual animals. (F) Tumor size in mice (n = 10) administered OTI dsTCR-transduced T
cells and then injected on opposing flanks with EL4 (control) or E.G7 (target) thymoma tumor cells.
DOI: 10.7554/eLife.19095.009
The following figure supplements are available for figure 4:
Figure supplement 1. N-terminal epitope tags do not impair surface expression of TCR chains.
DOI: 10.7554/eLife.19095.010
Figure 4 continued on next page
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The lack of TI-GvHD in mice receiving dsTCR-transduced T cells was not due to lack of function in
vivo. Mouse T cells transduced with OTI wtTCR or dsTCRC produced a similar complement of cyto-
kines upon stimulation with cognate peptide-MHC multimer (Figure 4—figure supplement 2). For
at least 6 weeks following T cell injection, Va2
+/Vb5
+ T cells were present in the spleen and retained
specificity for H-2Kb/Ova tetramer (Figure 4—figure supplement 3A). These splenic T cells exhib-
ited antigen-specific IFN-g release and modulated the surface expression of T cell activation markers
upon stimulation with ovalbumin peptide ex vivo (Figure 4—figure supplement 3B,C). The ovalbu-
min-expressing murine thymoma line, E.G7, grew in all control mice injected with LNGFR-transduced
T cells, but did not grow detectably in any mice injected with either wtTCR- or dsTCR-transduced T
cells (Figure 4E). Tumor cell killing was antigen-specific, because EL4 – the ovalbumin-negative
parental line from which E.G7 was derived – grew readily in mice injected with dsTCR-transduced T
cells (Figure 4F). The relative efficacies of wtTCR- and dsTCR-transduced T cells were compared by
titrating down the number of T cells injected prior to tumor cell injection. Both wtTCR- and dsTCR-
transduced T cells slowed tumor growth when mice were injected with 1 T cell per 500 tumor cells,
and prevented tumor growth entirely at higher tested ratios (Figure 4—figure supplement 4). Thus,
dsTCRs mediate antigen-specific immunity but not deleterious autoimmunity in vivo.
dsTCRs complement other strategies to improve efficacy and safety of
TCR gene therapy
Swapping TCR domains prevents mispairing with endogenous TCR chains, but also reduces the
amount of transduced TCR on the cell surface in the presence of competing endogenous TCR
chains. Accordingly, employing dsTCRs in adjunct with approaches to reduce endogenous TCR
expression may increase dsTCR surface expression while also improving the safety of these
approaches in a complementary manner. We explored the compatibility of dsTCRs with two such
approaches: knockdown of endogenous TCR in mature T cells, and hematopoietic stem cell TCR
gene therapy.
A recent report demonstrated that RNAi-mediated silencing of endogenous TCR genes improves
surface expression and reduces mispairing of a co-delivered codon-optimized TCR (Bunse, 2014).
However, TI-GvHD was not eliminated entirely, indicating incomplete knockdown of endogenous
TCR. We hypothesized that combining dsTCRs with endogenous TCR knockdown would improve
cell surface expression of dsTCRs while also eliminating TI-GvHD entirely. To investigate this combi-
nation approach, we transduced mouse T cells with vectors that co-delivered 1) shRNA targeting
endogenous TCR a and b genes and 2) codon-optimized wt- and dsTCR versions of the lymphocytic
choriomeningitis virus (LCMV)-specific P14 murine TCR. As previously shown (Bunse, 2014), the b
chain (Vb8) of P14 wtTCR was disproportionally detected on the cell surface relative to the a chain
(Va2) - indicative of mispairing - even when translational stoichiometry was ensured through the use
of a viral 2A sequence (Figure 5A). Co-delivery of shRNA resulted in knockdown of endogenous
TCR surface expression to ~40% of normal levels (Figure 5—figure supplement 1), improving the
balance of P14 wtTCR chains expressed on the surface and increasing tetramer staining (Figure 5A,
B). Reflecting the lack of mispairing exhibited by dsTCRs, the domain-swapped a and b chains were
detected in equal amounts on the cell surface with or without endogenous TCR knockdown
(Figure 5A). However, knockdown greatly improved surface expression and tetramer binding of the
P14 dsTCR by reducing competition for assembly with CD3 chains (Figure 5B).
Mice injected with P14 wtTCR-transduced T cells exhibited weight loss and developed TI-GvHD,
which was prevented by co-delivery of shRNA (Figure 5C–E). By contrast, no TI-GvHD was observed
Figure 4 continued
Figure supplement 2. Wild-type TCR- and dsTCR-transduced T cells secrete a similar complement of cytokines
upon stimulation.
DOI: 10.7554/eLife.19095.011
Figure supplement 3. Domain-swapped TCR-transduced T cells are functional in vivo.
DOI: 10.7554/eLife.19095.012
Figure supplement 4. Wild-type and domain-swapped TCR-transduced T cells similarly protect against tumor
growth
DOI: 10.7554/eLife.19095.013
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Figure 5. Complementarity of TCR domain-swapping and endogenous TCR knockdown. (A-B) Representative flow
cytometry plots showing percent of CD8+ T cells that are (A) Va2
+Vb8
+ and (B) gp33 tetramer+ following
transduction with a vector delivering codon-optimized gp33-specific P14 (Va2Vb8) TCR ± shRNA targeted to
endogenous TCR Ca/Cb. (C-E) Mouse model of TCR gene transfer-induced graft-vs-host disease (TI-GvHD), as in
Figure 4, except mice were administered T cells transduced with codon-optimized P14 TCR ± shRNA targeted to
endogenous TCR Ca/Cb. Respective group sizes, n = 8, 8, 13, 12, and 11. ***p<0.001, ****p<0.0001 ns, not
significant. (C) Mean percent initial body weight ± SD for each group over time. (D) Percent initial body weight of
surviving mice at 22 days after T cell administration. (E) Kaplan-Meier survival curve. (F-G) Flow cytometric
measurement of mispairing of (F) P14 TCRa and (G) P14 TCRb chains in murine splenic T cells transduced with
either chain ± shRNA targeted to endogenous TCR Ca/Cb. Histograms are representative of triplicate results from
3 independent experiments.
DOI: 10.7554/eLife.19095.014
The following figure supplement is available for figure 5:
Figure supplement 1. shRNA-mediated knockdown reduced endogenous TCR expression on surface of mouse T
cells.
DOI: 10.7554/eLife.19095.015
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in mice receiving P14 dsTCR-transduced T cells, whether or not shRNAs were co-delivered. As with
OTI dsTCR (Figure 4B), P14 dsTCR did not induce TI-GvHD because the P14 domain-swapped a
and b chains did not mispair with endogenous chains (Figure 5F,G). By contrast, individually deliv-
ered P14 wild-type a and b chains mispaired with endogenous chains even when both endogenous
chains were knocked down. In fact, knockdown of both endogenous chains increased mispairing of
P14 wta, suggesting the reduction of competing endogenous a enabled more mispairing of the
weak P14 wta with the remaining endogenous b chain. Prevention of TCR mispairing via endoge-
nous TCR knockdown therefore relies on both the reduction of endogenous TCR and the equal
(over)expression of the transduced TCR chains. Taken together, these results suggest that a combi-
nation approach of endogenous TCR knockdown and dsTCR transduction may optimize safety and
efficacy over either approach alone.
Hematopoietic stem cells (HSCs) transduced with pre-rearranged TCR genes differentiate into
antigen-specific T cells in the periphery (Vatakis et al., 2011; Yang and Baltimore, 2005). This is an
attractive therapeutic approach as it provides a continuous supply of antigen-specific naı¨ve T cells
with optimal replicative potential (Hinrichs et al., 2011). Additionally, expression of a pre-rear-
ranged TCR in HSCs suppresses rearrangement of the endogenous TCR in these cells via allelic
exclusion (Hinrichs et al., 2013; Vatakis, 2013). As allelic exclusion in TCR-transduced HSCs is
incomplete, however, there remains a risk that TCR mispairing can precipitate autoimmunity. HSCs
transduced with dsTCRs would retain the advantages of wtTCR-engineered HSCs while eliminating
the risk of autoimmunity. We injected HLA-A*0201+ immunodeficient (NSG) mice with F5 wtTCR- or
dsTCR-transduced human CD34+ HSCs. Three months after injection, A2/MART1-specific CD3e+ T
cells constituted up to 87.7% of human CD45+ thymocytes and up to 66.7% of human CD45+ CD19-
CD3e+ splenocytes in mice engrafted with dsTCR-transduced stem cells (Figure 6). Therefore,
dsTCRs are compatible with TCR-engineered HSC adoptive transfer.
Substitution of ab TCR constant domains with corresponding domains
from gd TCRs is a related strategy to prevent TCR mispairing
A subset of T cells encode gd TCRs, which share a broadly similar architecture to ab TCRs, are
somatically rearranged, associate with CD3 chains, and mediate antigen-specific cellular immunity,
but which are functionally distinct from ab TCRs (Attaf et al., 2015). Interestingly, ab TCR chains
transduced into gd T cells do not mispair with endogenous gd TCR chains (Saito, 1988; van der
Veken et al., 2006). These ab TCR-transduced gd T cells mediate antigen-specific immunity in vitro
and in mouse models (van der Veken et al., 2006, 2009). However, the relative paucity of gd T cells
in the blood, the requirement of co-delivery of CD4 and CD8 co-receptors, and the lower prolifer-
ative capacity and in vivo effector function of these cells relative to ab T cells are challenges of using
ab TCR-transduced gd T cells for adoptive cell therapies (van der Veken et al., 2006, 2009).
Ideally, the lack of mispairing between ab and gd TCRs could be exploited in the context of the
more abundant and co-receptor-expressing ab T cells. We explored swapping corresponding con-
stant domains of ab and gd TCRs as an approach to prevent mispairing that is conceptually related
to but distinct from our ab interchain domain-swapping approach. We designed three chimeric con-
structs in which the F5 TCR domains Va and Vb were fused to Cd and Cg (dsTCRCdg); VaCa and VbCb
were fused to cpd and cpg (dsTCRdg); or VaCa and VbCb were fused to cpg and cpd (dsTCRgd),
(Figure 7A). Mispairing between these constructs and wild-type endogenous ab TCR chains is
expected to be disfavored due to juxtaposition of ab and gd constant domains (Figure 7B).
Constructs were initially tested for surface expression and dextramer binding in transduced Jurkat
T cells. As with the interchain domain-swapped constructs (Figure 2B), chimeric domain-swapping at
the V-C junction resulted in loss of TCR surface expression (Figure 7C). By contrast, both dsTCRdg
and dsTCRgd expressed on the surface and bound cognate dextramer to a similar extent as wtTCR.
As expected, 3 of the 4 simulated mispaired constructs comprising one chimeric chain and one
wtTCR chain did not bind dextramer (Figure 7D,E). Only the wta/dsbg mispaired construct was
detected at a low level on the cell surface, binding dextramer at 20% the level of wtTCR
(Figure 7D). Dextramer binding results were similar in primary T cells, indicating that chimeric
dsTCRdg and dsTCRgd assemble with CD3 chains with similar efficiency as wtTCR in the presence of
competing endogenous TCR (Figure 7F; MFI for dsTCRdg and dsTCRgd = 157% and 174% that of
wtTCR, respectively). T cells expressing chimeric dsTCRs were activated and secreted IFN-g in
response to coincubation with cognate antigen-expressing target cells (Figure 7G,H). In contrast to
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Figure 6. dsTCR-transduced human HSCs develop into antigen-specific T cells in humanized mice. Flow cytometry
plots showing dissociated thymocytes or splenocytes from humanized mice stained with A2/MART1 tetramer and
anti-CD3e. Mice were injected with TCR-transduced HSCs three months prior to analysis. Mouse 3 and 4 are
replicates, mouse 5 and 6 are replicates. Mouse 2 has no replicate because wtTCR-transduced HSCs did not
engraft in Mouse 1 (not shown). Results are from a single experiment.
DOI: 10.7554/eLife.19095.016
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dextramer binding, these functional outputs were reduced for chimeric dsTCRs relative to wtTCR,
indicating chimeric domain-swapping partially impaired signaling capacity. Replacing the chimeric
TCR cytoplasmic signaling domains with those from ab TCR did not substantively alter the function
of chimeric dsTCRs (Figure 7—figure supplement 1). As observed in Jurkats, chimeric dsad, dsag,
and dsbd chains did not mispair productively with wild-type ab TCR chains (Figure 7F–H). Only the
wta/dsbg mispaired construct exhibited low levels of dextramer binding (7% of wt) and secreted
IFN-g (20% of wt), indicating some allowance for pairing between constant TCRa and TCRg domains.
Thus, substitution of constant domains of tumor-specific ab TCRs with corresponding gd TCR
domains produces a chimeric receptor that mediates functional, antigen-specific T cell immunity with
minimized mispairing risk.
Figure 7. Substitution of ab TCR constant domains with corresponding domains from gd TCRs prevents TCR mispairing. (A) Schematic of ab/gd
chimeric TCR architectures. Domains are swapped following the V domains (dsTCRCdg) or C domains (dsTCRdg and dsTCRgd). (B) Schematic of simulated
mispaired constructs, in which ab and gd constant domains are juxtaposed. Such mispairing is expected to be unproductive because ab and gd
constant domains do not interact. (C-E) Flow cytometry histograms comparing peptide-MHC multimer binding by Jurkat T cells transduced with (C) F5
wtTCR or ab/gd chimeric dsTCR constructs, (D) F5 wtTCR, F5 dsTCRdg and constructs simulating mispairing between these, or (E) F5 wtTCR, F5 dsTCRgd
and constructs simulating mispairing between these. Histograms are representative of triplicate results from 2 independent experiments. (F) Flow
cytometric measurement of percent of dextramer-binding TCR and LNGFR expressed on the surface of transduced primary human T cells. LNGFR is an
independent transduction marker expressed from the same vector as TCR. (G) Flow cytometric measurement of CD25 expressed on the T cell surface
and (H) ELISA measurement of secreted IFN-g from TCR-transduced primary human T cells following 48 hr coincubation with cognate or control
antigen-expressing K562 target cells. For panels (F-H), means ± SD for 3 technical replicates are shown.
DOI: 10.7554/eLife.19095.017
The following figure supplement is available for figure 7:
Figure supplement 1. Chimeric ab/gd dsTCRs function similarly with cytoplasmic domains derived from ab or gd TCRs.
DOI: 10.7554/eLife.19095.018
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Discussion
The promise of TCR gene transfer – to enable us to initiate or amplify beneficial immune responses –
is already coming to fruition in the field of cancer immunotherapy (Johnson et al., 2009; Mor-
gan, 2006; Davis, 2010; Parkhurst, 2011; Robbins, 2015, 2011). However, mispairing between
introduced and endogenous TCR chains produces autoreactive human T cells in vitro (van Loenen
et al., 2010) and causes graft-vs-host disease in mice (Bendle et al., 2010; Bunse, 2014), indicating
that TCR gene transfer poses a non-theoretical risk of autoimmunity. As the potency of TCR gene
therapy is augmented through combination with other immunotherapies (e.g. checkpoint blockade),
there may be a concomitant rise in mispairing-related serious adverse events. This work describes a
domain-swapping strategy to prevent TCR mispairing, thereby improving the safety of this promis-
ing approach.
By swapping constant domains between a and b chains of a clinically-relevant ab TCR, we gener-
ated a receptor that retains antigenic specificity and function but does not mispair with endogenous
TCRs. Interchain domain-swapped TCRs prevent mispairing-related autoreactivity through three
potential mechanisms: (1) dsTCR chains mispair with wtTCR chains inefficiently due to juxtaposition
of non-interacting domains (i.e. neither a nor b self-associate); (2) mispairing between wt and ds
chains results in a receptor that incompletely assembles with CD3 chains and is degraded; (3) mis-
paired wt/dsTCRs that escape degradation and express on the surface with an incomplete comple-
ment of CD3 chains will have impaired signaling capacity. Thus, proper dsTCR/CD3 complex
assembly is central to the differential function of correctly paired versus mispaired dsTCRs. The
detailed mechanism by which dsTCRs assemble with CD3 chains remains open. The transmembrane
domains and connecting peptides of wtTCRs participate in complex assembly while the ectodomains
contribute to complex stability and signaling (Call et al., 2002; Kuhns and Davis, 2007; Xu and
Call, 2006). The dsTCRs reorient these domains with respect to one another. Despite this, dsTCRs
assemble with CD3 chains with proper juxtaposition of CD3e chains, express on the cell surface, and
mediate functional, antigen-specific responses, including tumor cell killing. This indicates that
dsTCR/CD3 complexes preserve the transmembrane contacts between the TCR and CD3 chains that
are essential for complex assembly (Call et al., 2002). If transmembrane orientation is preserved, it
is unlikely that the short, rigid CD3 connecting peptides can contact the reoriented TCR ectodo-
mains, resulting in presumed (though undemonstrated) disruption of these stabilizing contacts. This
could account for the generally lower surface expression observed for dsTCRs relative to the wtTCR.
The dsTCRcp construct additionally reorients the connecting peptides with respect to the transmem-
brane domains, consistent with its generally lower surface expression relative to the dsTCRC con-
struct. That both of these constructs transduce extracellular ligand binding into intracellular signaling
suggests that the function of the TCR/CD3 complex is remarkably robust toward structural
perturbation.
The functional avidity of dsTCR-transduced T cells can be optimized for clinical application in sev-
eral ways. First, wtTCR- and dsTCR-transduced Jurkat T cells performed equivalently in functional
assays, indicating the importance of high transduction efficiency. Second, assembly of dsTCRs with
CD3 may be improved by reducing the number of endogenous TCRs competing for these chains. In
this work, we showed that dsTCRs are compatible with TCR-transduced HSC transfer, as well as with
shRNA-mediated knockdown of endogenous TCR genes. Combining dsTCRs with these adjunct
approaches improved cell surface expression of dsTCRs and safeguarded against mispairing with
residual endogenous TCR. Third, swapping domains closer to the V-C junction would avoid reorient-
ing constant domains with respect to each other, thereby preserving all contacts with CD3. We
attempted to optimize such a construct in this work (dsTCRV and dsTCRCdg), but found that all con-
structs that swapped domains at the V-C junction abrogated TCR surface expression completely.
Interestingly, a conceptually related approach has been used to ensure correct pairing of heavy and
light chains in bispecific antibodies (Schaefer et al., 2011), and the lead architecture (CrossMabCH1-
CL) from that application swapped domains at the V-C junction (i.e. the elbow). It is unclear why the
dsTCRV variant was entirely nonfunctional whereas analogously manipulated CrossMab antibodies
bind antigen with affinity comparable to wild-type Fab. This may be attributable to a more flexible
antibody hinge or to the specifics of how the domain-swap was achieved. Notably, the CrossMab
approach differed from ours in that domains were swapped asymmetrically between chains (i.e.
heavy chain residues were duplicated in the hinge/elbow region of both the heavy and light chains),
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so a similar modification to our approach may identify a functional dsTCR design that is swapped
near the V-C junction.
Finally, although we focus on TCRs relevant to cancer immunotherapy, domain-swapping was
applied successfully to all TCRs attempted, including four human TCRs and two mouse TCRs. Thus,
the general dsTCR approach can be applied broadly to TCRs of therapeutic interest, enabling devel-
opment of safer immunotherapies for a variety of cancers, infections, and autoimmune diseases.
Materials and methods
Materials
Primers were purchased from Integrated DNA Technologies (Coralville, IA). KOD polymerase master
mix and polybrene were purchased from EMD Millipore (Darmstadt, Germany). Sequencing was per-
formed by Retrogen Inc (San Diego, CA). Fluorescently labeled antibodies and 7-AAD for flow
cytometry were purchased from Biolegend (San Diego, CA), eBioscience (San Diego, CA), or Beck-
man Coulter (Brea, CA). Peptides were purchased from Anaspec Inc (Fremont, CA) or Thermo Fisher
Scientific (Waltham, MA). Anti-CD3 (OKT3) and anti-CD28 (CD28.2) activating antibodies were pur-
chased from eBioscience (San Diego, CA). Short-dated Proleukin was provided by Prometheus Labo-
ratories Inc (San Diego, CA) through an investigator-initiated trial program. All other cytokines were
purchased from Peprotech, Inc. (Rocky Hill, NJ). Concanavalin A was purchased from Sigma-Aldrich
(St. Louis, MO). RetroNectin was purchased from Clontech Laboratories (Mountain View, CA). BioT
transfection reagent was purchased from Bioland Scientific (Paramount, CA). Cell culture media, anti-
biotics, and fetal bovine serum were purchased from Corning (Corning, NY). Human AB serum was
purchased from Omega Scientific (Tarzana, CA). Peptides were purchased from Anaspec (San Jose,
CA).
Cell lines
293T/17, Jurkat E6-1, and K562 cells were purchased from the American Type Culture Collection
(Manassas, VA). Their identities were authenticated by STR analysis and they were confirmed to be
mycoplasma-free (DDC Medical, Fairfield, OH). 293T cells were grown in D10 media (Dulbecco’s
Modified Eagle Medium (DMEM) supplemented with antibiotics (penicillin/streptomycin) and 10%
(v/v) fetal bovine serum (FBS)). Jurkat and K562 cells were grown in C10 media ((RPMI 1640) medium
supplemented with antibiotics, 10% (v/v) FBS, 10 mM HEPES, 50 mM b-mercaptoethanol, 1x MEM
NEAA, and 1 mM sodium pyruvate). EL-4 and E.G7 mouse thymoma cell lines were provided by Lili
Yang (UCLA) and grown in C10 media. The cells were split every 2–3 days. All cells were grown and
assayed at 37˚C with 5% atmospheric CO2.
Animals
Female 6 wk old C57BL/6 J (B6) mice and B6.SJL-PtprcaPepcb/BoyJ (CD45.1 B6) mice were pur-
chased from Jackson Laboratory (Bar Harbor, ME) and housed in the California Institute of Technol-
ogy animal facility. Animals were granted access to food (PicoLab Rodent Diet 5053, PMI Nutrition
International, St. Louis, MO) and water ad libitum throughout the study. The room was maintained
on a 13:11 hr light:dark cycle. The ambient temperature remained between 71–75 ˚F with a relative
humidity of 30-70%. All injections (retroorbital, intraperitoneal, and subcutaneous) were performed
under anesthesia (isoflurane). Local anesthetic (0.5% proparacaine hydrochloride) was administered
following retro-orbital injections. Animals were sacrificed by controlled CO2 inhalation. Experiments
conducted at Caltech were approved by the Institutional Animal Care and Use Committee of the
California Institute of technology (IACUC protocol 1611).
Animals for TCR/shRNA combination experiments at MDC Berlin were purchased as 6 wk old
female C57BL/6 (Charles River (Sulzfeld, Germany) and housed at the MDC SPF facility. These
experiments were conducted in accordance with institutional and national guidelines, after approval
by a state animal ethics committee (Landesamt fu€r Gesundheit und Soziales protocol 0233/11). Ani-
mals for HSC transduction experiment were bred, housed, and monitored according to UCLA
Department of Laboratory Animal Medicine standards (UCLA Animal Research Committee protocol
2008–167).
Bethune et al. eLife 2016;5:e19095. DOI: 10.7554/eLife.19095 15 of 24
Research article Human Biology and Medicine Immunology
Peptide-MHC multimers
HLA-A2 and b2-microglobulin were expressed in E. coli, refolded in the presence of MART126-35
(A27L) (ELAGIGILTV) or NY-ESO-1157-165(C165V) (SLLMWITQV) heteroclitic peptides, purified, and bioti-
nylated as previously described (Toebes et al., 2006). Biotinylated H-2Kb/Ova257-264 monomers
were provided by the NIH Tetramer Core Facility (Atlanta, GA). Peptide-MHC monomers were
stored at  20˚C or  80˚C until use. Peptide-MHC tetramers were prepared from monomers using
fluorescently-labeled streptavidin from Molecular Probes (Eugene, OR) according to the NIH Tetra-
mer Core Facility protocol. Peptide-MHC dextramers were prepared by doping the tetramer assem-
bly reaction with biotinylated dextran (manuscript in preparation). Briefly, peptide-MHC and
fluorescently-labeled streptavidin were added at a molar ratio of 3:1 (1.5 mM:0.5 mM) and incubated
10 min. Biotinlyated dextran, MW 500 kDa (Molecular Probes) was then added to the incubation at
25 nM (1:20 with respect to streptavidin) and incubated an additional 10 min. Peptide-MHC multi-
mers were prepared fresh or stored briefly at 4˚C.
TCR, CD3, and pMHC single-chain trimer constructs
OTI TCR genes were obtained from Gavin Bendle (Univ. of Birmingham, UK). F5 TCR genes were
obtained from Steve Rosenberg (NCI, Bethesda, MD). 1 G4 TCR genes were obtained from Richard
Koya (RPCI, Buffalo, NY). M1 TCR genes and mouse and human CD3 genes were obtained from Lili
Yang (UCLA, Los Angeles, CA). Novel TCR architectures were prepared by assembly PCR. Amino
acid sequences of hybrid joints are provided within relevant figures. For epitope-tagged TCR con-
structs, Myc or V5 epitope tags were inserted between the leader sequence and the N-terminus of
the TCR chain. Peptide-MHC single-chain trimers of A2/NY-ESO-1(SLLMWITQV) and A2/MART1
(ELAGIGILTV) were prepared with a disulfide trap modification as described (Hansen et al., 2009).
Evaluation of TCR surface expression in transfected 293T
293T were plated (25 K/well on 96-well plate) a day prior to transfection. Cells in each well were
transfected with 0.2 mg each of plasmids encoding TCR, CD3d, CD3e, CD3g , and CD3z, using BioT
transfection reagent according to manufacturer’s instructions. Media was refreshed after 24 hr. Cells
were de-adhered from the plate using 2 mM EDTA in PBS, stained with fluorescent antibodies and
pMHC multimers in FACS buffer (2% FBS in PBS), and analyzed by flow cytometry 48 hr after
transfection.
Functional assays in jurkat T cells
TCR constructs were subcloned into a pCCLc-MND-based lentiviral vector in the format TCRa-F2A-
TCRb-P2A-Myc271. Myc271 is a novel chimeric transduction marker comprising the transmembrane
and truncated extracellular domains of CD271(LNGFR) fused to an extracellular cMyc epitope tag.
Lentiviral vectors were prepared from 293T producer cells. One day prior to transfection, 1 x 106
293T cells/well were plated on 6-well plates. In 100 mL PBS, added 1 mg TCR lentivector, 1 mg
pCMV-R8.2 (gag-pol helper plasmid), 0.2 mg pCAGGS-VSVG (pseudotyping helper plasmid), and 6.6
mL polyethyleneimine transfection reagent (Sigma) and incubated for 10 min. Fresh 2 mL media was
replaced on plated 293T, and then transfection mix was added to cells. 48 hr following transfection,
Jurkat T cells (10 (Johnson et al., 2009) cells/well in 250 mLC10) were added on a 24-well plate and
250 mL filtered (0.45 mm) viral supernatant was added to cells to initiate transduction. After 60–72 hr
of transduction, Jurkats were assayed for TCR surface expression and function. To test for surface
expression, cells were rinsed and stained with fluorescent antibodies and pMHC multimers in FACS
buffer, and analyzed by flow cytometry. Dead cells were excluded from analysis using 7-AAD. To
test for function, unselected Jurkat T cells were co-incubated in a 96-well plate at a 1:1 ratio with
K562 cells stably expressing control or cognate peptide-MHC single chain trimers. After 48 hr of
coincubation, the supernatant was tested for secreted interleukin-2 with a commercial ELISA kit
according to the manufacturer’s protocol (BD, Franklin Lakes, NJ).
Functional assays in primary human T cells
TCR constructs were subcloned into an MSCV-based retroviral vector in the format LNGFRD-P2A-
TCRa-F2A-TCRb. LNGFRD is a transduction marker comprising the low-affinity nerve growth factor
receptor with intracellular domain truncated. Retroviral vectors were prepared from 293T producer
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cells. One day prior to transfection, 6-well plates were coated with poly-L-lysine and 1 x 106 293T
cells/well were plated. On day of transfection, 2 mg TCR lentivector, 2 mg pHIT60 (gag-pol helper
plasmid), and 1.3 mg pRD114 (pseudotyping helper plasmid) were mixed in 100 mL 250 mM CaCl2.
DNA/CaCl2 was added while vortexing to 100 mL 2x HEPES-buffered saline (HBS), incubated 5 min,
and then added to cells in fresh D10 media. The day after transfection, media was replaced with
D10 containing 20 mM HEPES and 10 mM sodium butyrate, incubated 8 hr, and then media was
replaced with D10 containing 20 mM HEPES. Viral supernatant was harvested 40–48 hr after trans-
fection, filtered (0.45 mm), and used directly to transduce activated T cells.
Primary human peripheral blood mononuclear cells (PBMCs) were purchased from the CFAR
Virology Core Lab at the UCLA AIDS Institute. Two days prior to transduction, a 24-well plate was
coated with 1 mg/mL anti-CD3 (OKT3) and peripheral blood mononuclear cells were activated at
2 x 106 cells/mL on the anti-CD3 coated plate in the presence of 1 mg/mL anti-CD28 and 300 U/mL
IL-2 in T cell media (AIM-V media supplemented with 5% (v/v) human AB serum and antibiotics (pen/
strep)). On day of transduction, activated T cells were centrifuged with virus and 10 mg/mL polybrene
at 1350xg for 90 min at 30˚C. Following spinfection, virus was replaced with fresh T cell media sup-
plemented with 1 mg/mL anti-CD28 and 300 U/mL IL-2. 48 hr following transduction, transduced pri-
mary T cells were assayed for TCR surface expression. Functional assays were performed with
unselected transduced T cells as described for Jurkat T cells, except that after coincubation with
antigen-expressing K562 derivatives, surface expression of CD25 was measured for primary T cells
and the supernatant was tested with a commercial ELISA kit for secreted interferon-g (BD, Franklin
Lakes, NJ).
BaF3 proliferation assays
BaF3 cell lines were generated and analyzed by flow cytometry as previously described
(Kuhns et al., 2010; Lee et al., 2015). Briefly, Phoenix E packaging cells were used to generate ret-
rovirus for each cell line. In 6 cm plates, 3 mg of the desired retroviral construct along with 0.75 mg
gag polymerase and 0.75 mg eco envelope were mixed in DMEM with 10% FCS and then transfected
into 1 x 106 Phoenix E packing cells using Turbofect (Fermentas) according to the manufacturer’s
instructions. The next day, transfected Phoenix E cells were shifted to 32˚C after media change. Viral
supernatants were harvested at 48 and 72 hr post-transfection. The supernatants for all constructs
used to generate a cell line were pooled and concentrated to 250 ml using an Amicon Ultra 15 100
kDa (Millipore). BaF3 cells were co-transduced simultaneously with a polycistronic vector encoding
all CD3 chains (cytoplasmic domains truncated and CD3e fused to EpoR cytoplasmic domain) and a
vector encoding a TCR construct. Parental BaF3 cells (1 x 106) were plated in 2 ml of complete RPMI
in one well of a 12 well plate in 8 mg/ml polybrene, 1 ng/mL IL-3 (R and D Systems), and the viral
supernatant. Cells were then spun for 2 hr at 32˚C at 2700 rpm in a Legend XTR centrifuge (Thermo-
Fisher), after which the media was exchanged with fresh complete RPMI containing 1 ng/mL IL-3.
Transduced cells were cultured overnight at 37˚C prior to selection for eE expression with 10 mg/mL
puromycin (InvivoGen). Cells transduced with the 2B4 control TCR were selected with 10 mg/mL
puromycin and 100 mg/mL zeocin (LifeTech). BaF3 cells were split as necessary to keep them sparse
and under heavy drug selection. All cell lines were maintained at a density below 1 x 106/mL and
split the night before experiments to be in mid growth phase the day of the experiment.
Surface expression was assessed by flow cytometry with the following antibodies: anti-CD3e-PE-
Cy7 (clone 2 C11), anti-Va2-PE (clone B20.1), anti-Vb5-FITC (clone MR9-4), and HLA-A2/MART1(ELA-
GIGILTV) and H-2Kb/ovalbumin(SIINFEKL) dextramers. BaF3 cells (2.5 X 104/well) were setup in 96
well plates in triplicate under drug selection for a 3-day proliferation assay in the absence of IL-3.
Cells were enumerated by flow cytometry with count beads, which allowed the total cell number per
well to be extrapolated.
Adoptive transfer of transduced hematopoietic stem cells
Humanized mice were generated as previously described (Gschweng et al., 2014). Briefly, HLA-
A*0201+, CD34-enriched human peripheral blood stem cells were stimulated for 24 hr before trans-
duction with spin concentrated virus encoding the indicated constructs at a vector concentration of
1 x 108 transduction units/mL. Twenty four hours later, cells were collected, washed, and resus-
pended at a concentration of 2 x 107 cells/mL in X-VIVO-15 medium (Lonza). Neonatal (d3-5) NSG-
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A0201 mice (Jax 014570) received 1 Gy from a 137Cs source immediately before injection. A dose of
1 x 106 cells (50 ml) was delivered to each mouse via intrahepatic injection. Three months post-trans-
plant, mice were harvested for analysis. Thymus and spleen from each mouse was surgically excised
and dissociated over 70 mm strainers in RPMI + 10% FBS. Flow cytometry analysis was performed on
1 x 106 cells per sample, and stained with anti-mouse CD45, HLA-A2/MART1(ELAGIGILTV) multimer,
and the following anti-human antibodies: CD45, CD19, CD3, CD4, and CD8. Data were acquired on
an LSRFortessa (BD).
Mouse T cell transduction with OTI TCR constructs
Murine OTI TCR constructs were subcloned into the MSCV-based retroviral vector pMX in the format
TCRb-(F2A or IRES)-TCRa. Retroviral vectors were prepared from 293T producer cells. Two days
prior to transfection, 5 x 106 293T cells were seeded per 15 cm plate. On day of transfection, 11.25
mg retroviral vector (encoding OTI wtTCR, OTI dsTCR, or LNGFRD control) and 11.25 mg pCL-Eco
ecotropic packaging vector were mixed in 1000 mL serum-free DMEM. Transfection reagent (33.75
mL BioT) was added and transfection mix was immediately vortexed, incubated for 5 min, and then
added to cells in fresh D10 media. The following day, media was replaced on 293T and a Retronec-
tin-coated plate was prepared (24-well plate coated overnight with 30 mg/mL Retronectin overnight
at 4˚C and then blocked with 2% (w/v) BSA for 30 min at room temperature). Viral supernatant was
harvested at 48 and 72 hr after transfection, filtered (0.45 mm), and added directly to blocked Retro-
nectin-coated plates. Virus was bound to plate by spinning at 3000 xg for 120 min at 4˚C. Superna-
tant was removed immediately prior to adding activated T cells to virus-coated plate.
Primary mouse T cells were harvested from mouse spleen. Mouse spleens were dissociated and
treated with RBC lysis buffer (Biolegend) to remove erythrocytes. Mouse splenocytes (2 x 106 cells/
well on a 24-well plate) were activated in C10 containing 2 mg/mL concanavalin A and 1 ng/mL IL-7
for 24 hr. Activated T cells were pooled, supplemented with 4 mg/mL protamine sulfate, spun on the
virus-coated plate at 800 xg for 30 min at 32˚C, and then incubated in the presence of virus over-
night at 37˚C. The next day, cells were washed with PBS, and then transduced a second time on
fresh, virus-coated plates. The day after the second transduction, cells were counted and analyzed
for transgene expression by flow cytometry. TCR-transduced cells were evaluated directly for activity
or transferred to recipient mice for in vivo assays as described below.
Ensemble cytokine secretion detection
Mouse splenocytes (2 x 106 cells/well) were activated in 1 mL C10 containing 2 mg/mL concanavalin
A and 1 ng/mL IL-7 for 48 hr, then transduced with retroviral supernatant encoding OTI wtTCR, OTI
dsTCR, or no TCR as described. After overnight transduction, T cells were washed and incubated for
16 hr in either C10 media alone or media containing 1:100 H-2Kb/Ova tetramer (final 39 nM) and 1
mg/mL anti-CD28 (clone 37.51). Supernatants were collected after the 48 hr ConA/IL-7 activation
and after the 16 hr tetramer stimulation for ensemble proteomic analysis based on a DNA-encoded
Antibody Library (DEAL) assay (Bailey et al., 2007). Briefly, a DNA barcoded slide was sectioned
into wells using molded elastomers. The surface of the slide was blocked for 1 hr with 3% bovine
serum albumin (BSA, Sigma) in PBS buffer (Irvine Scientific). A cocktail of antibody-DNA conjugates
that capture the measured proteins was added and incubated for an hour in order to hybridize them
to the surface (Bailey et al., 2007; Ma et al., 2011). After washing the wells 3 times with 3% BSA,
the supernatant containing the secreted proteins was added to individual wells and incubated for an
hour. Afterwards, wells were washed again 3 times with 3% BSA. The assay was completed by apply-
ing biotinylated antibodies and streptavidin-Cy5 and a final wash with 3% BSA to remove excess
dye. Finally, the slide was washed with PBS before spin drying and scanning on a GenePix 4400A
fluorescent scanner (Molecular Devices).
Evaluation of TCR gene transfer-induced graft-vs-host disease (TI-
GvHD) in mice
The capacity of OTI wtTCR- and dsTCR-transduced T cells to induce graft-vs-host disease was evalu-
ated by an assay simulating TCR gene therapy in mice (Bendle et al., 2010). Donor mouse (CD45.1
B6) splenocytes were activated and transduced with retroviral supernatant encoding OTI wtTCR, OTI
dsTCR, or no TCR as described above. Recipient mice received 5 Gy from a 137Cs source to render
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them lymphopenic one day prior to T cell injection (d-1). The next day (d0), a dose of 1 x 106 trans-
duced cells (100 ml) was delivered to each mouse via retro-orbital injection. Initial body weight was
recorded on d10, after which mice received twice daily intraperitoneal injections of 7.2 x 105 U IL-2
(Prometheus Labs) for three days (d10-d12). Animals were monitored thereafter for signs of TI-GvHD
(i.e. cachexia), and mice were euthanized if body weight fell to 85% initial weight.
Ex vivo assay for splenic T cell activity
Donor mouse splenocytes were activated with ConA/IL-7, transduced with OTI wtTCR, dsTCR, or
control vector, and then injected retro-orbitally into lymphopenic recipient mice as described above.
Forty-four days following T cell injection, recipient mice were sacrificed and splenocytes were disso-
ciated, RBC-lysed, and seeded in a 48-well plate at 106 cells/mL in C10 alone or C10 containing 1
mg/mL ovalbumin257-264 (SIINFEKL) peptide. After 72 hr incubation, the supernatant was tested with
a commercial ELISA kit for secreted mouse interferon-g (BD) and the T cells were tested by flow
cytometry for surface expression of Va2 TCRa, Vb5 TCRb, H-2K
b/Ova257-264 tetramer-specific TCR,
and activation markers (anti-CD25 (clone PC61), anti-CD44 (clone IM7), and CD62L [clone MEL-14]).
Tumor xenograft experiments
A subset of mice evaluated for TCR gene transfer-induced GvHD were further tested for capacity of
transferred T cells to prevent tumor growth of tumor xenografts. Recipient mice were rendered lym-
phopenic by g-irradiation, injected with TCR-transduced T cells retro-orbitally, and monitored for TI-
GvHD as described above. Forty days following T cell injection, mice were injected on their right
flank subcutaneously with 5 x 106 ovalbumin-expressing E.G7 thymoma tumor cells. For tumor speci-
ficity experiment, mice were injected with OTI dsTCR-transduced T cells as above and 25 days there-
after injected subcutaneously with 5 x 106 E.G7 (target) thymoma tumor cells on the right flank and
5 x 106EL4 (control) thymoma tumor cells on the left flank. For T cell titration experiment, mice were
injected as above with unsorted splenocytes containing the specified number of transduced
(Va2
+Vb5
+) CD8+ T cells and 25 days thereafter injected with 5 x 106 E.G7 thymoma tumor cells. The
two longest perpendicular dimensions of each injected tumor were measured with calipers daily and
used to calculate the tumor cross-sectional area. Mice were euthanized if the longest dimension
measured 15 mm.
Evaluation of safety of dsTCR/shRNA combination therapy in mice
Retroviral vectors encoding codon-optimized TCR and shRNA targeting endogenous TCR a and b
genes were designed and produced as described (Bunse, 2014). Briefly, ecotropic virus particles
were produced using Platinum-E packaging cells and g-retroviral MP71 vector plasmids. Superna-
tants were harvested 48 hr after transfection, filtered (0.45 mm) and frozen ( 80˚C). Mouse spleno-
cytes were activated using concanavalin A (2 mg/ml, Sigma-Aldrich) and IL-7 (1 ng/ml, Peprotech) for
24 hr and then the first round of transduction was performed. The cells were transferred into virus-
coated plates, protamine sulfate (4 mg/mL, Sigma-Aldrich) was added and the plates were centri-
fuged (800 g, 32˚C) for 30 min. The virus-coated plates were prepared by centrifugation of Retronec-
tin-coated 24-well culture plates with 0.5 ml/well viral supernatant for 2 hr (3000 g, 4˚C). The next
day a second round of transduction was performed. After overnight incubation, the transduction
rate was determined and a population of cells containing 1 x 106 P14 TCR-expressing CD8 T cells
was transferred into mice (C57BL/6) that were treated 1 d before with total body irradiation (TBI, 5
Gy, X-Ray irradiator RS2000, Rad Source). Ten days after T cell injection, the mice received
7.2  105 (Johnson et al., 2009) IU Proleukin (Novartis) intraperitoneally twice a day for 3 d and
were monitored thoroughly (weight, appearance, behavior). Group assignments were blinded and
mice were sacrificed according to predefined human endpoints.
Flow cytometry assay for single chain mispairing
Human PBMCs were activated with anti-CD3/anti-CD28 and transduced with RD114-pseudotyped
virus as described above. To determine whether epitope tags affect TCR surface expression, T cells
transduced with F5 wtTCRa (± cMyc tag) and wtTCRb (± V5 tag) were analyzed by flow cytometry
using anti-cMyc and anti-V5 (Genscript, Piscataway, NJ) and anti-TCRb (clone JOVI.1) primary anti-
bodies, followed by anti-mouse IgG-PE secondary antibody. To measure mispairing of a single
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introduced F5 TCR chain with endogenous human TCR chains, T cells transduced with cMyc-
wtTCRa, cMyc-dsTCRa, V5-wtTCRb, or V5-dsTCRb individually were analyzed for surface expression
of introduced chains with anti-tag antibodies.
Similar analysis was performed with mouse OTI TCR in mouse T cells, but tags were not required
due to the availability of antibodies against the variable domains of OTI TCR (anti-mouse Va2 (clone
B20.1, Biolegend) and anti-Vb5.1/5.2 (clone MR9-4, Biolegend). Fresh mouse splenocytes were
depleted of T cells expressing endogenous TCRs with these variable domains by binding them with
anti-Va2-PE and anti-Vb5.1/5.2 PE and then removing bound cells using anti-PE microbeads and
MACS LD Separation Columns (Miltenyi Biotec, San Diego, CA) according to the manufacturer’s
instructions. Remaining T cells were activated with ConA/IL-7 and transduced as described above
with ecotropic virus encoding LNGFR (transduction marker) and either OTI wtTCRa, dsTCRa,
wtTCRb, or dsTCRb. Transduced T cells (gated on CD45.1+CD8a+LNGFR+) were analyzed for surface
expression of Va2 and Vb5.1/5.2 to measure mispairing of these single introduced OTI chains with
endogenous murine TCR chains.
Analysis of mispairing of P14 TCR chains (Va2 and Vb8) ± codelivered shRNA was conducted iden-
tically except that 1) recipient cells were depleted of endogenous Va2
+ and Vb8
+ cells prior to trans-
duction, and transduced cells were analyzed with anti-Va2 and anti-Vb8 (clone MR5-2, Biolegend)
and 2) transduced cells were cultured in media with 10 ng/mL IL-15 for 72 hr following transduction
and prior to flow cytometry analysis to enable endogenous gene knockdown by shRNA. Extent of
endogenous TCR knockdown was determined by flow cytometry, comparing the amount of TCR
complex (anti-TCRb (clone H57-597) and anti-CD3e (clone 145-2C11)) expressed on the surface of T
cells transduced with LNGFR ± shRNA
Statistics
Significance analysis of mouse survival (Kaplan-Meier) curves was conducted with the log-rank (Man-
tel-Cox) test. Significance analysis of mouse weight loss was conducted with one-way analysis of vari-
ance and Tukey’s post-test for multiple comparisons. A statistical probability of p<0.05 was
considered significant. No power analysis was conducted for animal experiments; the number of ani-
mals tested was based on budget and feasibility. No data were excluded as outliers. Descriptive sta-
tistics are presented as mean ± standard deviation of replicate assays. Technical replicates are
defined as replicate testing of tissue from the same mouse (only Figure 4—figure supplement 3) or
identical assays conducted on independent manipulations of the same cell line or primary T cell sam-
ple (e.g. activity assays employ T cell replicates transduced separately and coincubated separately
with target cells). Biological replicates are defined as identical experiments conducted in multiple
mice.
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